Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity - PubMed (original) (raw)
Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity
P Bevan. Neurosci Lett. 1983.
Abstract
This study reports the changes in the behavioural responsiveness of rats in the "Ungerstedt Model' following repeated injections of apomorphine. The changes in striatal [3H]haloperidol binding coincident with the behavioural responses are also estimated. Following unilateral lesions of the substantia nigra, the number of [3H]haloperidol binding sites in the ipsilateral striatum increase, and this effect correlates with the behavioural effect following a single apomorphine injection. Repeated apomorphine treatment, however, results in a decrease of neuroleptic binding sites in the ipsilateral and contralateral striatum accompanied by increased behavioural responses. Thus repeated apomorphine treatment discriminates the receptor mechanisms involved in the behavioural response from those receptors labelled by neuroleptics.
Similar articles
- Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
Staunton DA, Magistretti PJ, Shoemaker WJ, Deyo SN, Bloom FE. Staunton DA, et al. Brain Res. 1982 Jan 28;232(2):401-12. doi: 10.1016/0006-8993(82)90283-9. Brain Res. 1982. PMID: 6322915 - Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
Creese I, Burt DR, Snyder SH. Creese I, et al. Science. 1977 Aug 5;197(4303):596-8. doi: 10.1126/science.877576. Science. 1977. PMID: 877576 - Chemical and physiological aspects of the actions of lithium and antidepressant drugs.
Bloom FE, Baetge G, Deyo S, Ettenberg A, Koda L, Magistretti PJ, Shoemaker WJ, Staunton DA. Bloom FE, et al. Neuropharmacology. 1983 Mar;22(3 Spec No):359-65. doi: 10.1016/0028-3908(83)90184-3. Neuropharmacology. 1983. PMID: 6406928 Review.
Cited by
- L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.
Riederer P, Horowski R. Riederer P, et al. J Neural Transm (Vienna). 2023 Nov;130(11):1323-1335. doi: 10.1007/s00702-023-02692-9. Epub 2023 Oct 5. J Neural Transm (Vienna). 2023. PMID: 37796288 Free PMC article. Review. - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review.